Is venetoclax the new backbone of acute myeloid leukaemia therapy?

Lancet Haematol. 2021 Aug;8(8):e536-e537. doi: 10.1016/S2352-3026(21)00205-2.

Authors

Prachi Jain¹, Alice S Mims²

Affiliations

¹ Department of Internal Medicine, The Ohio State University, OH, USA.
² Department of Internal Medicine, The Ohio State University, OH, USA. Electronic address: [email protected].

PMID: 34329570
DOI: 10.1016/S2352-3026(21)00205-2

No abstract available

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Humans
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy*
Neoplasm, Residual / diagnosis
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
Sulfonamides / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Proto-Oncogene Proteins c-bcl-2
Sulfonamides
venetoclax